2022
DOI: 10.1016/j.lrr.2022.100341
|View full text |Cite
|
Sign up to set email alerts
|

Exploration of residual disease in stem cell products from mantle cell lymphoma using next-generation sequencing

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 18 publications
0
1
0
Order By: Relevance
“…The primary purpose of the developed swigh-score clonotyping tool is to facilitate the categorization and interpretation of FASTQ, the prevalent data format for presenting raw output from most DNA sequencing workflows. It offers commands that enable users to track the burden and development of a single clonotype, which can detect residual clonal B cells in various tissues, e.g., stem-cell products for autologous stem cell transplant [ 26 ] or blood plasma by sequencing cell-free tumor DNA [ 12 , [27] , [28] , [29] ]. Still, the utility and predictive value of MRD assessment varies among different diagnoses and cancer types, e.g., due to disease kinetics and available biomarkers, which can impact its clinical applicability [ 14 ].…”
Section: Additional Informationmentioning
confidence: 99%
“…The primary purpose of the developed swigh-score clonotyping tool is to facilitate the categorization and interpretation of FASTQ, the prevalent data format for presenting raw output from most DNA sequencing workflows. It offers commands that enable users to track the burden and development of a single clonotype, which can detect residual clonal B cells in various tissues, e.g., stem-cell products for autologous stem cell transplant [ 26 ] or blood plasma by sequencing cell-free tumor DNA [ 12 , [27] , [28] , [29] ]. Still, the utility and predictive value of MRD assessment varies among different diagnoses and cancer types, e.g., due to disease kinetics and available biomarkers, which can impact its clinical applicability [ 14 ].…”
Section: Additional Informationmentioning
confidence: 99%